No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NGNE Neurogene
- 34.130
- -1.850-5.14%
Close Jul 5 16:00 ET
- 35.020
- +0.890+2.61%
Post 18:21 ET
443.02MMarket Cap-12051P/E (TTM)
35.865High33.670Low69.48KVolume35.780Open35.980Pre Close2.38MTurnover1.17%Turnover RatioLossP/E (Static)12.98MShares53.00052wk High2.59P/B203.11MFloat Cap12.20052wk Low--Dividend TTM5.95MShs Float1115.000Historical High--Div YieldTTM6.10%Amplitude7.500Historical Low34.300Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Neurogene to Participate in BMO Genetic Medicines Summit
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will
Express News | Neurogene To Be Added To Russell 3000 Index, Effective At Open On Jul. 1
Neurogene Announces Addition to Russell 3000 Index
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Neurogene will be added to
Express News | Neurogene Shares Are Trading Higher After BMO Capital Initiated Coverage on the Stock With an Outperform Rating and Announced a $65 Price Target
Express News | Neurogene Inc : BMO Initiates Coverage With Outperform Rating; Target Price $65
Neurogene Initiated at Outperform by BMO Capital
Neurogene Initiated at Outperform by BMO Capital
Comments
$Neurogene(NGNE.US$
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg